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Background
The JAK2 V617F mutation has been noted in the cases of polycythemia vera, essential 
thrombocythemia, and primary myelofibrosis patients. This mutation occurs less fre-
quently in acute myeloid leukemia (AML) and other hematologic diseases, such as myelo-
dysplastic syndrome (MDS); myelodysplatic syndrome/myeloproliferative neoplasm, 
unclassifiable (MDS/MPN-U); and refractory anemia with ring sideroblasts with throm-
bocytosis (RARS-T). 
Methods
Patients diagnosed with hematologic diseases other than MPN who visited Seoul St 
Mary’s Hospital from January 2007 to February 2010 were selected. A total of 43 patients 
were enrolled in this study: 12 MDS, 9 MDS/MPN-U, 7 RARS-T, and 15 AML patients. 
The diseases were diagnosed according to the 2008 WHO classification criteria. Data ob-
tained from JAK2 V617F mutation analysis and cytogenetic study as well as complete 
blood count and clinical data were analyzed. 
Results
Of the 43 patients, 6 (13.9%) harbored the JAK2 V617F mutation. The incidence of the 
JAK2 V617F mutation in each patient group was as follows: 8.3% (1/12), MDS; 22.2% 
(2/9), MDS/MPN-U; 14.3% (1/7), RARS-T; and 13.3%, (2/15) AML. The platelet count was 
higher than 450×10
9/L in 3 of the 6 patients (50%) harboring the JAK2 V617F mutation, 
and it was in the normal range in the remaining 3 patients. Among the 6 patients, 1 MDS 
and 1 MDS/MPN-U patients had the 46,XX,del(20)(q11.2) karyotype. 
Conclusion
The JAK2 V617F mutation is associated with an increased platelet count in MDS, 
MDS/MPN-U, RARS-T, and AML patients. Cytogenetic abnormalities of del(20)(q11.2) oc-
curred in 1/3 of patients with the JAK2 V617F mutation but further studies are required 
to confirm this association.
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INTRODUCTION
  A somatic mutation in JAK2 V617F in hematopoietic stem 
cells has been reported to cause increased sensitivity to eryth-
ropoietin and independent growth to growth factor [1]. The 
mutation is commonly found in a majority of patients with 
myeloproliferative neoplasm (MPN) characterized by pro-
liferation of one or more of the myeloid cell lineages in 
the bone marrow and circulating immature cells in the pe-
ripheral blood. The mutation occurs in 95% of patients with 
polycythemia vera and 50% of patients with essential throm-
bocythemia and primary myelofibrosis and in other diseases Korean J Hematol 2010;45:46-50.
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Table 1. Clinical characteristics and JAK2 V617F mutation status of patients based on the diagnosis.
Variable MDS (n=12) MDS/MPN-U (n=9) RARST (n=7) AML (n=15)
Age
a) 67 (36-74) 65 (53-69) (49-74) 40 (16-80)
Sex
Men 7 6 3 9
Women 5 3 4 6
WBC (×10
9/L) 2.3 (0.9-30.9) 5.2 (2.1-21.9) 5.1 (4.9-839.5) 23.1 (0.9-139.6)
Hb (g/dL) 9.5 (6.0-11.0) 9.0 (7.9-11.4) 10.1 (7.0-12.0) 9.4 (5.0-12.2)
PLT (×10
9/L) 118 (11-362) 356 (63-1,250) 695 (519-1565) 110 (19-2,120)
MCV (fL)  90.7 (83.5-107.3) 90.5 (79.8-100.2) 102 (89.6-108.0) 91.4 (78.3-124.1)
MCH (pg) 30.9 (27.9-35.2) 28.5 (23.9-32.8) 34.6 (29.2-36.0) 30.8 (24.5-41.6)
MCHC (g/dL) 32.9 (30.3-35.9) 31.9 (28.9-34.3) 33.3 (32.6-35.8) 33.5 (28.9-36.7)
BM cellularity (%) 50 (10-100) 95 (50-100)  90 (40-100) 100 (50-100)
BM blast (%) 10 (0-15) 2.0 (0-9) 1 (1-3) 70 (21-98)
JAK2 V617F mutation (%) 1/12 (8.3) 2/9 (22.2) 1/7 (14.3) 2/15 (13.3)
Cytogenetics
Normal 7 3 6 5
1-2 abnormalites 3 5 1 6
Complex karyotype 2 1 0 4
Survival (month) 11 (1-61) 12 (1-76) 30 (19-76) 15 (2-39)
a)All the continuous variables are presented as median (range).
Abbreviations: MDS, myelodysplastic syndrome; MDS/MPN-U, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable; 
RARS-T, refractory anemia with ring sideroblasts with thrombocytosis; AML, acute myeloid leukemia; BM, bone marrow.
included in this category, except chronic myelogenous leuke-
mia [2]. The JAK2 V617F mutation is uncommon in other 
disease category with a few reports of variable incidence; 
further, no reports of this mutation in Korean patients exist. 
In this study, the JAK2 V617F mutation was studied in pa-
tients with hematologic diseases other than MPN.
MATERIALS AND METHODS
1. Patients
  In this study, we included patients who were examined 
for the JAK2 V617F mutation at Seoul St. Mary’s Hospital 
from January 2007 to February 2010. Forty three patients 
were enrolled, and the patients were grouped on the basis 
of their diagnosis according to the 2008 WHO classification 
as follows [8]: 12, myelodysplastic syndrome (MDS); 9, mye-
lodysplatic syndrome/myeloproliferative neoplasm, unclassi-
fiable (MDS/MPN-U); 7, refractory anemia with ring side-
roblasts with thrombocytosis (RARS-T); 15, acute myeloid 
leukemia (AML). One case of acute panmyelosis with fibrosis 
(APF) was included in the AML group. Three refractory 
cytopenia with multilineage dysplasia (RCMD) patients, 4 
refractory anemia with excess blasts (RAEB)-1 patients, and 
5 RAEB-2 patients were included in the MDS group. In 
case of AML patients, the regimen for induction chemo-
therapy with idarubicin and behenoyl arabinofuranosylcy-
tosine (BHAC) was administered and transplantation was 
performed as previously reported [3]. In the case of MDS 
patients, most of them were treated with azacitidine, and 
in the case of MDS/MPN-U patients, hydroxyurea was 
administered. The clinical characteristics and laboratory data 
including the karyotyping results of the patients are listed 
in Table 1.
2. JAK2 V617F mutation study
  DNA was extracted from bone marrow aspiration samples 
with the QIAamp DNA Blood Mini Kit (Valencia, CA, USA) 
and quantified by spectrophotometry (NanoDrop Technolog-
ies Inc, Wilmington, DE). The JAK2 V617F study was per-
formed by the melting curve analysis method. Melting curve 
analysis was performed using the Real-Q
TM JAK2 V617F 
detection kit (BioSewoom Inc, Seoul, Korea) and Hotstar 
Taq plus DNA polymerase (Qiagen, Valencia, CA.) in the 
Rotor gene 6000 (Valencia, CA, USA). A melting temperature 
of approximately 75±0.1
oC was considered to be indicative 
of the presence of the JAK2 V617F mutation and a temper-
ature over 76
oC, indicative of the absence of the mutation 
(Fig. 1). In case of 4 RARS-T patients, JAK2 exon12 mutation 
analysis by the melting curve method was performed as 
sufficient DNA was obtained from these patients [4, 5].
3. Statistical analysis
  Descriptive and statistically analyzed data were based on 
variables collected at the time of initial diagnosis. The Kruskal 
Wallis test was used to compare the 4 disease groups, and 
the Mann Whitney U-test was used in the case of variables 
that showed statistical significance against each group for 
that variable. Mann Whitney U-test was also used to compare 
the group with the JAK2 wild-type allele with the group 
containing the JAK2 V617F mutation. To determine the asso-
ciation between the JAK2 V617F mutation status and the Korean J Hematol 2010;45:46-50.
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Fig. 1. JAK2 Exon14 (V617F) test performed by the melting curve 
analysis method. Analysis of positive control (purple) and positive 
V617F mutation in an RARS-T patient (green) with a melting curve at 
75
oC (indicated with star shape) and another 5 controls with wild-type 
alleles (arrow). 
Table 2. Clinical and laboratory data of JAK2 V617F-positive cases.
Age Sex Diagnosis Cytogenetics
WBC
(×10
9/L) 
Hb
(g/dL)
PLT
(×10
9/L)
Cellularity
(%)
Blast
(%)
Treatment
Survival
(mo)
Outcome
40 F AML 46,XX,del(10)(q22q26)
[6]/46,XX[14]
1.6 7 194 80 60 alloPBSCT 21 Alive
18 F APF 47,XX,+8 [18]/46,XX[2] 2.9 10.1 703 100 21 uPBSCT 15 Alive
53 F MDS/MPD-U 46,XX,del(20)(q11.2) 2.6 8.3 1,143 100 3 Azacitidine,  alloPBSCT 76 Alive
66 F MDS/MPN-U  46,XX 9.8 10.8 356 100 2 Hydroxyurea  FU loss FU loss
72 F RAEB 46,XY,del(20)(q11.2) 6.7 9.8 362 NA NA Conservative 61 Alive
68 M RARS-T 46,XX 26.9 11.2 1,565 90 1 HydroxyureaAnagrelide 19 Alive
Abbreviations: AML, acute myeloid leukemia; APF, acute panmyelosis with fibrosis; MDS/MPN-U, myelodysplastic syndrome/myeloproliferative
neoplasm, unclassifiable; RAEB, refractory anemia with excess blasts; RARS-T, refractory anemia with ring sideroblasts with thrombocytosis; 
alloPBSCT, allogenous peripheral blood stem cell transplantation; uPBSCT, unrelated donor peripheral blood stem cell transplantation; FU loss, 
follow up loss; NA, not available.
platelet count, linear by linear association was performed. 
All statistical analyses were performed using the Medcalc 
software 9.0 (Medcalc, Mariakerke, Belgium).
  All the P-values were 2-tailed and statistical significance 
was set at the level of P＜0.05. The overall survival (OS) 
was defined as the length of time from the date of diagnosis 
to the date of death caused by factors related to the diagnosed 
disease.
RESULTS
  T he  JA K 2 V617F mu tat ion  was iden t if ie d in 6 o f  43 (13.9%) 
patients. The incidence of the JAK2 V617F mutation in each 
diagnosis group was as follows: 8.3% (1/12), MDS; 22.2% 
(2/9), MDS/MPN-U; 14.3% (1/7), RARS-T; 13.3% (2/15), 
AML (Table 1). The JAK2 exon12 mutation study conducted 
in 4 RARS-T patients revealed that all of them harbored 
wild-type allele.
  The platelet count of patients with the JAK2 V617F muta-
tion was higher than 450×10
9/L in 3 of the 6 patients (50%), 
and it was within normal range in the remaining 3 patients 
(Table 2). The median platelet count in the JAK2 V617F 
mutation group was 532×10
9/L (range, 194×10
9/L to 1,562× 
10
9/L), this value is much higher than that in the case of 
the JAK2 wild-type group which had a median platelet count 
of 158×10
9/L (range, 11×10
9/L to 2,120×10
9/L) (P＜0.01) (Table 
3). In addition, linear by linear association analysis showed 
that the JAK2 V617F mutation and platelet count were pos-
itively correlated with a value of 3.831 (P=0.05).
  Among the 6 patients with the JAK2 V617F mutation, 
4 showed an abnormal karyotype. Two patients each in the 
MDS and MDS/MPN-U groups, respectively, had a karyotype 
of 46,XX,del(20)(q11.2). The karyotypes of the other 2 were 
46,XX,del(10)(q22q26)[6]/46,XX[14] and 47,XX,+8 [18]/46,XX 
[2], respectively. There were 2 more MDS patients with 
the karyotype del(20)(q11.2) among the 37 patients with 
the JAK2 V617F wild-type allele. The other complete blood 
count (CBC) parameters, including the RBC count, Hb levels, 
WBC count, and RBC indices, were not significantly different 
between the JAK2 V617F mutation group and wild-type 
group. 
DISCUSSION
  The JAK2 V617F mutation has been reported to be strongly Korean J Hematol 2010;45:46-50.
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Table 3. Comparison of clinical characteristics  and laboratory 
data of the JAK2 mutation group and the JAK2 wild-type group.
　
JAK2 wild type
(n=37)
JAK2 V617F
(n=6)
Age
a) 58 (16-80) 59.5 (18-72)
Sex
Male 24 1
Female 13 5
Diagnosis
MDS 11 1
MDS/MPN-U 7 2
RARS-T 6 1
AML 13 2
Complete blood count
a)
WBC (×10
9/L) 4.9  (0.9-139.6) 4.8  (1.6-26.9)
Hg (g/dL) 9.3 (5.0-12.3) 9.9 (7.0-11.2)
PLT (×10
9/L) 158 (11-2,120) 532 (194-1,562)
MCV (fL)  91.2 (78.3-108.0) 91.9 (81.6-124.1)
MCH (pg) 30.8 (24.5-36.0) 29.7 (23.9-41.6)
MCHC (g/dL) 33.1 (28.9-36.7) 31.3 (29.0-33.5)
Cytogenetics
Normal 19 2
1-2 abnormalities 11 3
Complex karyotype 7 1
Survival (mo) 13 (1-75) 21 (15-76)
a)All the continuous variables are presented as median (range)
Abbreviations: MDS, myelodysplastic syndrome; MDS/MPN-U, mye-
lodysplastic syndrome/myeloproliferative neoplasm, unclassifi-
able; RARS-T, refractory anemia with ring sideroblasts with throm-
bocytosis; AML, acute myeloid leukemia.
associated with the pathogenesis of polycythemia vera. This 
mutation causes hyperproliferation of erythrocytes, gran-
ulocytes, and platelet precursors in the bone marrow in other 
types of MPNs also [6]. The incidence of this mutation is 
6.7% in MDS [7], 40% in MDS/MPN-U [8], 53% in RARS-T 
[8], and 1.8% to 28.0% in AML [9-14]. 
  In this study of Korean patients, the JAK2 V617F mutation 
was identified in 6 of 43 (13.9%) patients. The incidence 
of the JAK2 V617F mutation in each diagnosis group was 
as follows: 8.3%, MDS; 22.2%, MDS/MPN-U; 14.3%, RARS- 
T; and 13.3%, AML. The MDS/MPN-U cases account for 
2% of all the cases classified as MDS [15], and the incidence 
of the JAK2 mutation in this study was 22.2% (2/9) compared 
to the 40% (2/5) reported in literature [8]. Few reports of 
MDS/MPN-U along with the JAK2 V617F mutation exist, 
and further studies are required to evaluate the incidence 
of this mutation in these patients. It was noted that the 
incidence of the JAK2 V617F mutation in this study was 
lower in RARS-T and MDS groups [16-18]. This discrepancy 
might be caused by ethnic variation or by the population 
size being too small in previous reports as well as in this 
study. The incidence of the JAK2 V617F mutation in the 
AML cases in this study was 13.3% (2/15), which was within 
the range mentioned in previous reports. 
  The JAK2 V617F mutation is especially associated with 
increased platelet counts [19]. However, the exact mecha-
nism underlying this increase is not known. From previous 
reports, megakaryopoiesis was enhanced when the progeni-
tors are heterozygous for JAK2 V617F, whereas erythropoi-
esis is strongly stimulated when the progenitors are homo-
zygous for the JAK2 V617F mutation [19]. In this study, 
patients with the JAK2 V617F mutation had an increased 
platelet count compared to those with wild-type JAK2, which 
was consistent with the results of a previous study [20]. 
These data suggest that the pathogenesis of thrombocytosis 
in patients with these 4 diseases might be similar to that 
in the case of essential thrombocytosis. Interestingly, 2 of 
6 patients with the JAK2 V617F mutation showed a karyotype 
of del(20)(q11.2). Previous literature reported that 18.4% 
of primary myelofibrosis patients with the JAK2 V617F muta-
tion harbored del(20)(q11.2) whereas 6.9% with the wild- 
type JAK2 harbored this karyotype, which is the 2
nd most 
common karyotype after the normal karyotype [21, 22]. In 
this study, 1 MDS patient had both the JAK2 V617F mutation 
and harbored del(20)(q11.2). The del(20)(q11.2) karyotype 
was not found in RARS-T or AML patients. This result sug-
gests that no correlation between the JAK2 V617F mutation 
and del(20)(q11.2) exists in cases of primary myelofibrosis, 
MDS, MDS/MPN-U, RARS-T, or AML. There were 2 more 
patients with del(20)(q11.2) among the remaining 37 (5.4%) 
without the JAK2 V617F mutation. This result suggests that 
del(20)(q11.2) might be associated with the JAK2 V617F 
mutation.
  In conclusion, the JAK2 V617F mutation is associated with 
increased platelet count in MDS, MDS/MPN-U, RARS-T, 
and AML patients. Cytogenetic abnormalities of del(20) 
(q11.2) occurred in 1/3 of patients with the JAK2 V617F 
mutation, but further studies are required to confirm this 
association.
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